微调BCL6的长期瘤控制
Shiki Takamura1, Aneela Nomura1, Masato Kubo2
1Laboratory for Immunological Memory, IMS RIKEN Center for Integrative Medical Science, Yokohama, Japan.
Science immunology
|October 20, 2023
概括
转录因子BCL6作为瘤内的CD8+原始细胞的关键守门员. 它防止了它们的过度分化,维持了类似茎的种群,以持续控制瘤.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 分子生物学分子生物学
背景情况:
- CD8+ T 细胞对于抗瘤免疫力至关重要.
- 瘤微环境可能会损害T细胞功能.
- 维持功能性T细胞池对于长期控制癌症至关重要.
研究的目的:
- 研究转录因子BCL6在调节瘤内CD8+原始细胞功能中的作用.
- 了解BCL6如何影响T细胞分化和瘤微环境中的持久性.
主要方法:
- 分析转录因子BCL6在瘤透的CD8+T细胞中的表达.
- 评估CD8+原始细胞分化状态.
- 评估BCL6对T细胞干细胞样性质和瘤控制的影响.
主要成果:
- BCL6充当门卫,控制瘤中CD8+原始细胞的分化.
- BCL6 阻止了这些细胞的过度末端分化.
- 通过BCL6保护类似干细胞的CD8+原始细胞,有助于长期控制瘤.
结论:
- 转录因子BCL6对于维持瘤中功能性的CD8+原生细胞至关重要.
- BCL6的守门员功能对于维持抗瘤免疫力和改善长期瘤控制至关重要.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538


